NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
Receptor Life Sciences, Inc.
United States
- Seattle, Washington
- 07/04/2022
- Series A
- $9,700,000
Receptor Life Sciences combines proven drug delivery technologies, compelling therapeutic candidates, and traditional drug development research practices to pursue a robust range of prescription drug treatments for CNS indications.
The delivery technologies, used in both oral and inhaled FDA-approved prescription drug products, represent a validated, strategic approach to overcoming traditional challenges of cannabinoid medicine. Receptor’s patented product candidates hold the potential to provide prescription treatments for a range of unmet medical needs, including anxiety and agitation in autism.
More information is at www.ReceptorLife.com.
- Industry Pharmaceutical Manufacturing
- Website https://receptorlife.com/
- LinkedIn https://www.linkedin.com/company/receptor-life-sciences-inc./
Related People
Mark TheeuwesFounder
United States -
Greater Philadelphia
Experienced Pharmaceutical Executive with a demonstrated history of working in all aspects of Clinical and Commercial Execution.
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)